Last reviewed · How we verify
Ifupinostat Hydrochloride for Injection
Ifupinostat is a histone deacetylase (HDAC) inhibitor that blocks HDAC enzymes to promote anti-tumor gene expression and immune activation.
Ifupinostat is a histone deacetylase (HDAC) inhibitor that blocks HDAC enzymes to promote anti-tumor gene expression and immune activation. Used for Hematologic malignancies (phase 3 development), Solid tumors (investigational).
At a glance
| Generic name | Ifupinostat Hydrochloride for Injection |
|---|---|
| Also known as | BEBT-908 for Injection, CUDC-908 |
| Sponsor | BeBetter Med Inc |
| Drug class | Histone deacetylase (HDAC) inhibitor |
| Target | Histone deacetylase (HDAC) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting histone deacetylases, ifupinostat increases acetylation of histone and non-histone proteins, leading to altered chromatin structure and reactivation of tumor suppressor genes. This mechanism also enhances immune cell function and can sensitize cancer cells to other therapies, making it a potential combination agent in oncology.
Approved indications
- Hematologic malignancies (phase 3 development)
- Solid tumors (investigational)
Common side effects
- Thrombocytopenia
- Anemia
- Nausea
- Fatigue
- Diarrhea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ifupinostat Hydrochloride for Injection CI brief — competitive landscape report
- Ifupinostat Hydrochloride for Injection updates RSS · CI watch RSS
- BeBetter Med Inc portfolio CI